Estimating stroke risk CHA 2 
DS 2 VASc score
To decide if OAC is clinically indicated, assessment of patients' stroke risk is required. The CHA 2 DS 2 VASc score was developed to estimate stroke risk in patients with AF. A higher score signifies a higher stroke risk.
Modified CHA 2 DS 2 VASc score
In the absence of other risk factors, female gender alone may not increase stroke risk. 6 There seems to be no benefit from anticoagulating patients with CHA 2 DS 2 VASc score = 0 for males and CHA 2 DS 2 VASc score = 1 for females. 7 Recent guidelines have also disregarded gender when deciding if a patient requires anticoagulation. 8 The modified CHA 2 DS 2 VASc (mCHA 2 DS 2 VASc) is used in this Appropriate Care Guide, where gender does not contribute to the score.
Assessing and addressing bleeding risk
It is important to assess and address bleeding risk throughout the full duration of anticoagulation. Annual major bleeding risks in patients on anticoagulation range from 3.1 to 3.4% for warfarin and 2.1 to 3.6% for NOACs. [11] [12] [13] Most of these were gastrointestinal bleeds and less frequently, intracranial haemorrhages.
Generally, bleeding risk scores, such as HAS-BLED, poorly predict major bleeding events.
14 However, they are useful in identifying risk factors that may be modifiable such as:
• concomitant drugs which may predispose to bleeding, such as NSAIDs and antiplatelet agents • excessive alcohol consumption (≥ 8 units per week) • poorly-controlled blood pressure • less than 6 in 10 INRs within the therapeutic range for warfarin. 
Warfarin
Warfarin is the only drug with proven safety and efficacy in patients with mechanical heart valves or moderate to severe mitral stenosis. 16, 17 The presence of either condition is associated with exceptionally high thromboembolic risks. Warfarin is the treatment of choice for these patients.
When patients on warfarin have INR levels which are not in therapeutic range, more frequent INR monitoring and dose adjustments are needed. 18, 19 Mild bleeding episodes can be managed in outpatient settings while severe bleeding episodes warrant hospitalisations. If reversal of anticoagulation is required, patients may be referred to specialists or the emergency department. This will facilitate management of potential complications and also encourage adherence.
INR monitoring
For patients initiated on warfarin, perform INR test:
• at baseline,
• weekly, until INR is within therapeutic range and
• at 8 to 12 weekly intervals once INR is stable.
• Frequent drug-drug, drug-food or drug-herb interactions.
• A narrow therapeutic range.
• The need for at least 6 out of 10 INR readings to be within therapeutic range.
• A delayed onset and offset of anticoagulation which may necessitate bridging therapy.
INR Management
Greater than therapeutic range but < 4.5
Decrease or withhold dosage.
Monitor INR more frequently if clinically indicated, and restart warfarin at a lower dose when INR is within therapeutic range.
4.5-9.0
Withhold warfarin and consider administering oral vitamin K at 1-3 mg.
Recheck INR within 24-48 h. If within range, resume warfarin at a lower dose. If INR is still high, administer a second dose of oral vitamin K at 1-3 mg.
> 9.0
Withhold warfarin and consider administering oral vitamin K at 3-5 mg.
Recheck INR
within 24-48 h. If within range, resume warfarin at a lower dose. If INR is still high, administer a second dose of vitamin K at 1-3 mg. Non-vitamin K antagonist oral anticoagulants (NOACs)
Diminished role of antiplatelet agents
These drugs are also known as direct oral anticoagulants (DOACs) or target-specific oral anticoagulants (TSOACs). With the lack of head-tohead trials, there is insufficient evidence to recommend one NOAC over the others in terms of safety and efficacy.
NOACs are as effective as warfarin in reducing AF-related strokes and systemic embolisms. They are also associated with fewer intracranial haemorrhages (ICH) compared to warfarin (about 2 to 5 ICH events avoided for every 1,000 patients treated per year). 20 However, they may be associated with increased gastrointestinal bleeding when compared to warfarin. 21 Limited experience with reversal agents may make NOACs less preferable in patients with high bleeding risks.
Antiplatelet agents are inferior to anticoagulants in AF-related stroke prevention and are no longer recommended in recent guidelines. 8 Compared to antiplatelet agents, anticoagulants reduced the absolute risk of all strokes by 0.7 to 7% while increasing the absolute risk of major bleeding by 0.2%. 28, 29 When anticoagulation is contraindicated, the role of antiplatelet agents is unclear. Some studies showed that aspirin caused more harm compared with no treatment 30, 31 while others showed fewer 32, 33 and less severe 34 strokes. Therefore, consider aspirin or clopidogrel only when anticoagulation is contraindicated in patients with mCHA 2 DS 2 VASc ≥ 2, especially for those with a history of ischaemic stroke or transient ischaemic attack.
Coagulation tests are not useful in patients on NOACs, except in cases of severe bleeding or urgent surgery. INR is not specific for NOACs and a normal prothrombin time or activated prothrombin time does not rule out the presence of residual NOACs' effects. 26 Estimate renal function using the Cockcroft-Gault formula as this method was used in the pivotal trials.
Table 3. Using NOACs in valvular heart disease (VHD)

Renal function monitoring Use Cockcroft-Gault formula
11-13
(140 -Age) × Body Weight (kg)
× Serum Creatinine (micromol/L)
• Multiply the value by 0.85 for females.
• Use ideal body weight for patients who are overweight.
VHD subgroup Evidence NOACs Use
Mechanical heart valves or moderate to severe mitral stenosis None Bioprosthetic heart valves, tricuspid regurgitation or mild mitral stenosis Limited 
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